Insilico Medicine and Human Life Foundation Models, Inc., a newly launched unit of Human Longevity, announced a multi-million-dollar co-development collaboration to build large-scale AI foundation models dedicated to human longevity science, according to the company.
Insilico will lead multimodal foundation model development, deep learning system engineering and model training and benchmarking using the MMAI Gym framework.
HLFM will combine those technical capabilities with Human Longevity’s de-identified multi-omic, imaging and longitudinal clinical datasets drawn from over a decade of research and thousands of individuals.
The companies say the jointly developed models are intended to enable earlier detection of age-related disease, predictive health risk modeling and AI-driven therapeutic discovery, and the company claims the models will be commercially available to support preventive and personalized interventions.
Insilico is described as a clinical-stage generative ai–driven biotechnology firm that listed on the Hong Kong Stock Exchange on 30 December 2025.
